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Abstract—Electrical vagus nerve stimulation is a treatment 
alternative for many epileptic and depressed patients whose 
symptoms are not well managed with pharmaceutical therapy. 
However, the fixed stimulus, open loop dosing mechanism limits 
its efficacy and precludes major advances in the quality of 
therapy. A real-time, responsive form of vagus nerve stimulation 
is needed to control nerve activation according to therapeutic 
need. This personalized approach to therapy will improve 
efficacy and reduce the number and severity of side effects. We 
present autonomous neural control, a responsive, biofeedback-
driven approach that uses the degree of measured nerve 
activation to control stimulus delivery. We demonstrate 
autonomous neural control in rats, showing that it rapidly learns 
how to most efficiently activate any desired proportion of vagal 
A, B, and/or C fibers over time. This system will maximize 
efficacy by minimizing patient response variability and by 
minimizing therapeutic failures resulting from longitudinal 
decreases in nerve activation with increasing durations of 
treatment. The value of autonomous neural control equally 
applies to other applications of electrical nerve stimulation.  
Index Terms—Biofeedback, electrical stimulation, neural 
control, neuroprosthesis 
I. INTRODUCTION 
AGUS nerve stimulation (VNS) is a treatment 
alternative for many epileptic and depressed patients 
whose symptoms are not well managed with pharmaceutical 
therapy. Approximately 2-weeks after device implantation, a 
physician programs the pacemaker-like device to deliver 
intermittent pulses of current to the left cervical vagus nerve. 
The highest efficacy is typically observed after 1 year, but 
only after several minimally informed stimulus parameter 
adjustments [1, 2]. The efficacy of these treatments is far from 
optimal. 
Over the course of weeks to months, a physician 
systematically tunes the stimulus until the patient and 
physician feel that the therapy is working with no adverse or 
intolerable side effects. If a bothersome side effect is 
encountered, the intensity of stimulation is decreased until the 
side effect disappears. These parameters are maintained until 
the next appointment [1, 2]. Major limitations beyond the 
subjective nature of this approach include 1) the risk of 
adaption or desensitization to the stimulus, which may make 
the therapy less effective over time (e.g., stimulus induced 
depression of neuronal excitability, or SIDNE [3]), 2) the lack 
of feedback regarding the type and number of neurons that are 
activated when the therapy is effective, and 3) the risk of 
patient discomfort [1].  
All electrical nerve stimulation (ENS) therapies use some 
form of a stimulus parameter-based dosing system. This is 
problematic, as stimulus parameters are poor predictors of 
therapeutic efficacy; each patient and nerve responds uniquely 
to the same strength of stimulation, and the relationship 
between stimulation and the degree of nerve activation 
changes over time. These factors limit treatment benefit and 
contribute to poorer efficacy on a shorter timescale [2]. They 
also help to explain why the therapeutic mechanisms are not 
well understood despite decades of investigation [1]. An 
objective, informed dosing system is required to improve the 
efficacy of ENS therapies and to further reduce the number 
and severity of side effects.  
We present autonomous neural control (ANC), a nerve 
activation control system designed to eliminate patient 
response variability and the detrimental effects of the foreign-
body response at the device-tissue interface. In rats, ANC 
rapidly learns how to most efficiently activate any proportion 
of vagal A, B, and/or C fibers over time. It provides a new 
dosing mechanism based on neural activation. In real time, 
ANC systematically decodes evoked compound nerve action 
potential (CNAP) responses to construct a patient-specific 
nerve activation profile (NAP), which describes how each 
neuron population in the nerve will respond to any strength of 
stimulation. Over the course of ENS therapy, ANC 
continuously refines the NAP to improve its prediction 
accuracy and adapt to circadian, drug-induced, or immune-
mediated changes at the device-tissue interface (Fig. 1) [4]. 
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ANC refines the electrical stimulus, within safe limits [3, 5-
7], to selectively control nerve activation on a patient-to-
patient, nerve-to-nerve and neuron-to-neuron basis. By 
providing consistent nerve activation, ANC allows 
reproducible experiments to systematically delineate the 
therapeutic mechanisms of VNS or other form of ENS 
therapy. Furthermore, biological markers of treatment 
response may be measured and classified with respect to the 
NAP, simplifying the development of fully personalized, 
closed-loop control systems for treating diverse neurological 
diseases. 
For physicians, ANC will 1) establish an objective, 
standardized dosing system based on the level of nerve/neuron 
activation or inhibition, expressed as a % of maximal 
nerve/neuron activation, 2) eliminate the complicated, time-
consuming stimulus parameter tuning process, 3) provide a 
simple mechanism to adjust the relative ratios of A, B and C 
fiber activation, and 4) ensure that therapeutic nerve/neuron 
activation is maintained over time. For patients, ANC will 1) 
improve efficacy and enhance the overall quality of ENS 
therapy, 2) reduce the number of doctor visits, and 3) help 
extend device lifetime by reducing energy waste from 
excessive stimulation. 
II. METHODS 
A. Surgical Methods 
All surgical and animal handling procedures are approved 
by the Institutional Animal Care and Use Committee (IACUC) 
and adhere to guidelines set forth in the Guide for the Care 
and Use of Laboratory Animals [8]. All rats are housed in a 
12-hr light/dark cycle at constant humidity and temperature. 
The surgical suite and instruments are sterilized prior to each 
procedure. Isoflurane gas anesthesia is used for the duration of 
surgery; it is set to the lowest level that will maintain a stable 
anesthetic plane (0.5-3% isoflurane in 2 L/min O2). Following 
induction, the rat is placed in a supine position, the surgical 
site is shaved and cleaned with alternating scrubs of betadine 
and 70% ethanol, and an analgesic is provided (butorphanol 
tartrate; 0.5-2 mg/kg, SC). A small support is placed below the 
neck for stability. Throughout the procedure, subcutaneous 
fluids are provided as needed to prevent dehydration. 
Once the surgical site is clean, a 1.5 to 2 cm long midline 
incision is made from the jaw line to manubrium. A blunt 
dissection technique is used for the remaining steps of the 
procedure. With a pair of curved, blunt-tipped scissors, we 
tunnel through the subcutaneous tissues until the sternohyoid, 
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Fig. 1. Summary and applications of ANC. ANC enables rapid, consistent control over the biological conduits of therapy. Using features from the 
CNAP, ANC rapidly constructs a NAP to predict how one or more neuron populations in a nerve will respond to any rectangular, constant-current 
stimulus pulse. The NAP enables dial based-control over the biology, simplifying device optimization and standardizing therapeutic, investigational and 
data reporting methods. 
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omohyoid, and sternocleidomastoid muscles are visible. The 
connective tissue between the left sternocleidomastoid and the 
sternohyoid/omohyoid is carefully separated until the carotid 
sheath is visible. Using a small pair of surgical retractors to 
hold the muscles apart, the vagus nerve and carotid artery are 
dissected from the carotid sheath. After isolating a 1.0 to 1.5 
cm segment of the cervical vagus nerve, the epineurium is 
carefully pierced with iris scissors and retracted with fine 
forceps. 
Two custom-made silicone cuff electrodes are wrapped 
around the nerve; care is taken to ensure circumferential or 
near-circumferential contact with the nerve (Electrode spacing 
= 1 mm; Electrode surface area ≅ 3 mm2). The stimulation 
leads are connected to the output of an A-M Systems Model 
2200 Analog Stimulus Isolator. The recording leads are 
connected to the inputs of a Grass Model P511 High 
Performance AC Preamplifier. The stimulation leads are 
connected such that the cathode (-) is closest to the non-
inverting recording electrodes. A data acquisition board 
(National Instruments USB-6353 X Series) is used to interface 
with a computer running ANC in Matlab R2010a. 
B. Stimulus Artifact Suppression 
A limited CNAP conduction distance is available along the 
left cervical vagus nerve of rodents (e.g., ~5-15 mm of 
exposed nerve in a 280-300 g rat). As a result, CNAP response 
peaks often coincide with the stimulus artifact, necessitating 
the use of an artifact suppression method [9]. To the best of 
our knowledge, we are the first to demonstrate effective and 
reliable stimulus artifact suppression using cathode-first, 
alternating monophasic stimulation in the peripheral nervous 
system at conduction distances less than 1 cm. 
Fig. 2 summarizes the method of CNAP extraction and 
averaging using the measured response to a 1-s train of 
cathode-first, alternating monophasic stimulation (Ist = 
stimulus pulse amplitude = 0.058 mA; tst = stimulus pulse 
width = 0.4 ms; PRF = pulse repetition frequency = 20 Hz; 
ttrain = stimulus train duration = 1 s; Fs = sampling frequency = 
50 kHz; pass-band = 0.001 to 10 kHz). The raw cathodal and 
anodal stimulus artifacts are shown in black and grey, 
respectively. To remove any DC offset, the average of the raw 
response waveform is subtracted from the recording. Then, 
ANC segments the raw response waveform into N periods of 
responses (N = PRF*ttrain = 20). Each period of the response 
waveform is then further segmented and grouped into clusters 
of cathodal and anodal response waveforms, respectively (Fig. 
2B). The cathodal and anodal stimulus artifacts are symmetric 
in the recordings due to the symmetry of the anodal and 
cathodal phases of stimulation and the natural orientation of 
the recording electrodes along equipotential lines of the 
electric field radiating from the stimulating electrodes. The 
sum of each anodal and cathodal response waveform yields a 
cluster of artifact-free vagal nerve responses to stimulation 
(Fig. 2C). The mean CNAP response waveform (Fig. 2E) is 
the averaged cluster of CNAP responses in Fig. 2C and the 
sum of the mean cathodal and anodal response waveforms in 
Fig. 2D. A Shapiro-Wilk test for normality gives no evidence 
that the artifact-free stimulus responses are not normally 
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Fig. 2. Summary of the cathode-first, 
alternating-monophasic stimulation 
method used by ANC [9]. ANC 
suppresses stimulus artifacts via a 
symmetric stimulation method in which 
the cathodal and anodal phases of 
stimulation have an identical shape and 
opposite polarity. In most cases, nerve 
fibers are only activated in response to the 
cathodal pulse (the inset overlays the 
stimulus waveform in red). ANC clusters 
each cathodal and anodal response to a 
train of biphasic stimuli (A), clusters the 
cathodal and anodal response waveforms 
(B), computes the artifact-free responses 
to each period of stimulation by summing 
the cathodal and anodal responses within 
a period of stimulation (C), computes the 
mean cathodal and anodal response 
waveforms (D), and sums the resulting 
waveforms to yield the mean CNAP 
response (E). The 95% confidence 
interval is shown in red in (E). 
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distributed (Prob>z = 0.889 when stimulating at 20 Hz for 1 
s). Therefore, a response at any point in the signal is 
significantly different from 0 V (at α = 0.05) if the mean 
response and 95% CI do not cross the abscissa. 
C. Nerve Response Classification 
ANC deconstructs the stimulus-evoked CNAP, recorded at 
a fixed distance from the stimulating cathode, to estimate the 
level and type of nerve fiber activation. Conduction velocity is 
used to identify distinct nerve fiber groups (i.e., neuron 
populations), referred to as A (fast, myelinated fibers), B 
(slow, myelinated fibers), or C (slow, unmyelinated fibers) 
[10, 11]. Fig. 3 describes this Letter System using data 
collected from the left cervical vagus nerve of a female Long-
Evans rat. When recording at a fixed, known distance from the 
stimulating cathode, the CNAP response waveform peaks 
separate in time due to the differing conduction velocities of 
A, B and C fibers. The maximal CNAP response, otherwise 
referred to as maximal activation, is the CNAP response 
magnitude at which an increase in stimulus intensity does not 
produce an increase in response. By individually deriving 
stimulus-response relationships for A, B and C fibers, the 
effect of any stimulus pulse on nerve activity is directly 
measurable. Before ANC, however, this information has not 
been readily available or exploited in therapeutic applications. 
Fig. 3. CNAP classification system built into ANC. (A) Mean CNAP response 
from the left cervical vagus nerve of rat. Shaded regions in (A) correspond to 
a conduction velocity range in (B), which enables nerve fiber classification 
according to the Letter System [15]. (B) Mean CNAP response from (A) 
plotted as a function of conduction velocity, in m/s (Conduction Distance = 
8.0 ± 0.5 mm). 
D. Stimulus-Response Measurement and Classification 
ANC measures a series of stimulus-response relationships 
to construct an empirical model that describes how each fiber 
type in any nerve of any patient will respond to any strength of 
electrical stimulation. This model, known as a nerve activation 
profile, describes the sensitivity and dynamic range of each 
fiber type that can be identified in a CNAP. It can be 
constructed in under a minute. ANC continuously updates the 
NAP to improve its prediction accuracy over time and adapt to 
the variety of factors that influence the efficacy of stimulation 
(e.g., circadian effects, changes in the electrode-tissue 
interface over time, or fiber desensitization to stimulation). By 
controlling nerve activation through dynamic adjustments to 
stimulus charge, accomplished through NAP-guided changes 
in stimulus pulse amplitude or width, ANC enables ENS with 
a constant nerve activation effect in each patient. This enables 
much more consistent therapy. 
The sensitivity of each fiber group to ENS is evaluated 
using stimulus-response data collected at tst = 0.4, 0.2 and 0.1 
ms. If necessary, the operator may define all stimulus and 
recording parameters (default parameters: stimulus type = 
constant current; stimulus waveform = cathode-first, 
alternating monophasic stimulation; PRF = 20 Hz; ttrain = 1 s; 
Fs = 50 kHz; pass-band = 0.001 to 10 kHz). Starting with tst = 
0.4 ms, ANC incrementally increases the stimulus amplitude, 
stimulates the nerve, and records that resulting CNAP 
response. Between trials, the mean CNAP response is 
computed, the peak fiber responses are located and classified, 
and the data are stored in local memory. Following Trial 1, the 
response magnitude from the target fiber group is always 
compared to that from the previous trial. When stimulus 
intensity is increased and the target fiber response magnitude 
no longer increases (i.e., if a fiber group is maximally 
activated), ANC stores the stimulus parameters and responses 
from the previous trial. Next, ANC decreases the stimulus 
amplitude according to (1) until parameters that yield a 
predefined percentage of maximal activation are located (e.g., 
25% maximal activation, defined as a target fiber response 
having a magnitude that is 25% of its maximal response 
magnitude). The same process is repeated using tst = 0.2 and 
0.1 ms, respectively. An error tolerance of 5% is initially used 
to classify all fiber response magnitudes to account for the 
effects of noise. 
(1) 
In (1), Qn-1 is the stimulus charge per phase from the most 
recent trial (in C/Ph),  is the target fiber response voltage 
(in V), VCNAP,n-1 is the fiber response voltage from the most 
recent trial, and k is a scaling factor that modulates the 
magnitude of the stimulus intensity adjustment (e.g., when k is 
greater than unity, it reduces the intensity of the stimulus 
charge adjustment; when k is less than unity, it amplifies the 
intensity of the stimulus charge adjustment). The new stimulus 
pulse amplitude is calculated by dividing the new stimulus 
charge per phase, Qn, by the pulse duration used in the 
preceding trial (i.e., ). 
III. RESULTS
A. Rapid Loss of C-fiber Activation with Constant 
Stimulation 
Fig. 4 shows an example of how a nerve adapts to a 
constant electrical stimulus in a relatively short time (Ist = 0.2 
mA; tst = 0.5 ms; PRF = 20 Hz; ttrain = 30 s). Suppl. Fig. 1 
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shows another example of activation loss using 10x less 
charge per phase. In both cases, the Aγ, B and C fiber CNAP 
responses rapidly evolve over 30-s of constant current 
stimulation (see esp. Fig. 4E-F). 
Linear regression was performed in STATA 12 to test for a  
statistically significant order effect, a characteristic feature of 
SIDNE [3]. A regression model slope coefficient that is 
significantly different from 0 suggests a relationship/change 
among the CNAP features of interest (i.e., Aγ+, B+, or C+) and 
stimulus number (i.e., the sequential number assigned to each 
cathodal stimulus pulse within the 30-s train of stimuli 
delivered at 20 Hz). Significance tests of the slope coefficients 
suggest that, with an increasing number of stimuli, Aγ fiber 
excitability increases (p-value = 4.82E-9) and C fiber 
excitability decreases (p-value = 5.34E-74). A change in 
stimulus-driven nerve activation suggests an analogous change 
in output to tissues innervated by the nerve. 
B. Autonomous Stimulus-Response Measurement and 
Classification 
Fig. 5 summarizes a set of stimulus-response data that ANC 
collected from C fibers in the left cervical vagus nerve of the 
same rat whose data is represented in Fig. 4 and 
Supplementary Fig. 1 (PRF = 20 Hz; ttrain = 1 s; Conduction 
Distance = 8 mm; NCNAP = 66 trials x 20 CNAP responses/trial 
= 1320 CNAP responses). Fig. 5A-C shows all 1320 Aγ, B, 
and C fiber CNAP response latencies and voltages (Nparameter = 
20 responses per stimulus parameter combination; Ncombo = 66 
unique parameter combinations). Although Aγ and B fiber 
stimulus-response data is collected, all stimulus intensity 
adjustments are based on the magnitude of the mean C fiber 
response in relation to the maximal response voltage. In Fig. 
5D, data from Fig. 5A-C is clustered by response voltage and 
latency. Local minima from each fiber group are also plotted 
to demonstrate that other features of the CNAP response, such 
as peak-to-peak voltage and area, can be measured and used 
by ANC. A color map of all 1320 CNAP responses is shown 
in Fig. 5E (voltage is represented as a color according to the 
scale to the right of the figure). Finally, the mean CNAP 
responses are plotted by trial in Fig. 5F. Mean peak latencies 
are computed from the latencies of each individual stimulus 
response shown in Fig. 5A-E. 
Suppl. Figs. 2 and 3 summarize data sets collected from Aγ 
and B fibers in the same nerve of the same subject (Suppl. 
Figs. 4-5 show data sets collected for C fibers in the same 
nerve of the same subject using a PRF of 2 and 1 Hz, 
respectively). Note how the mean C fiber response magnitude 
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varies with Qst in Fig. 5, whereas the mean Aγ and B fiber 
response magnitudes vary with Qst in Suppl. Figs. 2-3, 
respectively. The preferential modulation of Aγ, B, or C fiber 
groups implies that the activation level of any fiber group in 
the nerve can be selectively controlled if the appropriate set of 
stimulus parameters are known. 
C. The Slope-Activation Relationship 
ANC rapidly identifies the parameter space for each fiber 
group in a nerve in the form of an activation profile. An 
activation profile is autonomously constructed for each fiber 
type using measured stimulus-response data and a newly 
discovered mathematical formula that relates threshold current 
(i.e., rheobase current) to fiber activation level. A set of 
activation profiles for each fiber group in a nerve constitutes a 
nerve activation profile. 
The key to constructing a NAP is in a newly discovered, 
predictable relationship between the rheobase current, IRh, and 
its corresponding fiber activation level, λ (IRh is the slope of a 
charge-duration (CD) line described by the Weiss equation). 
When all possible CD lines are constructed from a set of 
stimulus-response data, each will represent a unique activation 
level, λ. If the slope of each line (i.e., IRh) is plotted against its 
corresponding activation level, λ, an exponential slope-
activation relationship is observed. It is unique to each subject, 
nerve and neuron type, and allows ANC to adapt to changes at 
the device-tissue interface over the course of an experiment or 
therapy. To our knowledge, this is the first discovery and 
documentation of the relationship. 
To derive the slope-activation relationship for vagal Aγ, B 
and C fibers, ANC first sorts the stimulus-response data in 
ascending order by the evoked response voltage. Each fiber 
response voltage is then normalized with respect to the 
maximal recorded response voltage and converted to a 
percentage of maximal activation. The largest observed 
response voltage represents maximal activation. All associated 
stimulus parameters are stored along with the measured nerve 
responses. 
Next, ANC clusters the evoked fiber responses and 
associated stimulus parameters by activation level (a 5% error 
tolerance is used by default). Within each cluster, the data is 
sorted by pulse duration (i.e., tst). If multiple entries have the 
same pulse duration and evoke the same level of activation, 
they are replaced with an average of the duplicate entries. 
ANC then searches for clusters with at least 2 pulse durations 
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Fig. 5. Autonomously collected stimulus-response data from the left cervical vagus nerve of a female Long-Evans rat. (A) Stimulus charge per phase, in 
nC/Ph, for the entire vagal C-fiber activation profile-mapping period (ANC constructs a unique activation profile for each stimulated nerve and neuron 
type; the activation profile serves as a guide when maintaining or adjusting nerve activation for an experimental or therapeutic purpose). The insets show 
the pulse duration and amplitude of each stimulus. (B) Measured Aγ, B and C peak response latencies relative to stimulus onset (ms). Latency increases 
with decreasing stimulus intensity for Aγ and C fibers, but not for B fibers. (C) Measured Aγ, B and C fiber peak response amplitudes relative to baseline 
(µV). (D) Clustered stimulus response data from B-C. Amplitude and latency values associated with the second deflection of the diphasic fiber responses 
are also plotted in grey. (E) A color map representation of all stimulus response data shown in A-C (NCNAP = 66 trials x 20 CNAP responses/trial = 1320 
CNAP responses). Stimulus onset occurs at the intersection of the Stimulus # and tCNAP axes. (F) Mean CNAP response computed from data collected 
during each trial of stimulation (NCNAP, avg = 20 CNAP responses/trial). Stimulus onset is at the intersection of the VCNAP, avg and tCNAP axes. 
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represented. Using these data, ANC computes the best-fit CD 
lines using least-squares linear regression. 
The slope of each computed CD line (i.e., IRh) is plotted 
against the associated percent maximal fiber activation, λ. To 
model the slope-activation relationships, ANC first computes 
the natural logarithm of each slope. Then, the best linear fit to 
the natural logarithm-transformed data is computed using 
least-squares linear regression. The resulting equation has the 
form , where  is the percent 
maximal activation, a is the predicted slope of the CD line for 
0% maximal activation, and r is a constant that determines the 
rate at which the slope of a CD line increases as activation 
level increases. In linear form, the slope-activation equation is 
. If  and , 
then , where M is the slope, B is the y-intercept 
(i.e., the threshold current for 0% maximal activation), and λ 
is the percent maximal activation. This can be used in place of 
IRh within the Weiss equation. In doing so, an equation that 
can be used to predict how a target fiber group will respond to 
any strength of ENS is created (2). The Weiss equation is 
shown above (2) for reference. 
 
  (2) 
  
Fig. 6 shows the slope-activation data along with the 
associated equations and goodness-of-fit metrics for vagal Aγ, 
B and C fibers (derived using stimulus response data from Fig. 
5 and Supplementary Figs. 2-3). The slope-activation data for 
Aγ fibers is least variable (R2 = 0.98), followed by C (R2 = 
0.86) and then B fibers (R2 = 0.36). A consistently poor signal-
to-noise ratio is likely to blame for the poor fit to B fiber 
slope-activation data. A poor fit to the slope-activation data 
will translate to larger predictive errors once the activation 
maintenance mode of ANC is initiated. The model will evolve 
as ANC collects more data, however. Erroneous or inaccurate 
values in the slope-activation relationship are replaced once 
ANC locates the stimulus parameters that yield precisely the 
desired response. A simple voltage clamp enables ANC to 
rapidly and precisely locate the true parameter set that evokes 
the target response. 
 
D. The Nerve Activation Profile 
The activation profile for each fiber type is formed from the 
slope-activation equation and an estimate of the SD time 
constant, τSD. The absolute value of the mean of the x-
intercept values from the CD lines is used as an estimate of 
τSD. Given the subject, nerve, and fiber-specific constants M, 
B, and τSD, (2) predicts the population response of any nerve 
fiber group to any strength of constant-current stimulation. 
This unique attribute is especially evident when solved for λ 
in (3). 
 
      
λ =
1
M ln
Ist ⋅ tst
tst +τ SD
$
%
&
'
(
)− B
+
,
-
.
/
0      
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Fig. 7 graphically depicts the activation profiles that ANC 
constructed for vagal Aγ, B and C fibers using (2). The 
activation profile can be expressed in CD (top row) or SD 
form (bottom row). When the activation profile from each 
fiber group is overlaid, the NAP is complete. The NAP in Fig. 
7 describes how the left cervical vagus nerve of one particular 
rat will respond to any strength of electrical stimulation. To 
aid interpretation, predicted CD lines (top row) and SD curves 
(bottom row) are shown within the parameter space for [0, 10, 
20, ..., 100]% maximal activation. Note the nonlinear increase 
€ 
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Fig. 6. Slope-activation data for Aγ (left), B (middle) and C fibers (right) for a single animal. For each fiber group, the rheobase current, IRh, is plotted 
against its corresponding level of maximal activation, λ. Data shows an exponential increase in rheobase current for a linear increase in percent 
maximal activation. Best-fit curves are calculated for each fiber type through a least-squares linear regression of the natural logarithm-transformed 
slope-activation data. The coefficients M and B of the slope-activation equation are placed in the generalized form of the Weiss equation, producing a 
single equation that predicts how the target fiber type will response to any strength of stimulation. The goodness-of-fit is best for Aγ fibers (R2 = 
0.98), followed by C and B fibers (R2 = 0.86 and 0.35, respectively). A poor fit is most closely associated with a poor signal-to-noise ratio. 
0 25 50 75 100
0
0.1
0.2
0.3
h (%)
I R
h (
m
A)
 
 
IRh data (Aa fibers)
IRh = e
0.0255h −10.97; R2=0.98
0 25 50 75 100
0
0.1
0.2
0.3
h (%)
 
 
IRh data (B fibers)
IRh = e
0.0145h −10.15; R2=0.35
0 25 50 75 100
0
0.1
0.2
0.3
h (%)
 
 
IRh data (C fibers)
IRh = e
0.0143h −10.63; R2=0.86
1534-4320 (c) 2013 IEEE. Personal use is permitted, but republication/redistribution requires IEEE permission. See
http://www.ieee.org/publications_standards/publications/rights/index.html for more information.
This article has been accepted for publication in a future issue of this journal, but has not been fully edited. Content may change prior to final publication. Citation information: DOI
10.1109/TNSRE.2014.2351271, IEEE Transactions on Neural Systems and Rehabilitation Engineering
IEEE TRANSACTIONS ON NEURAL SYSTEMS AND REHABILITATION ENGINEERING, VOL. XX, NO. X, XXX 2014 
 
8 
in slope with a linear increase in percent maximal activation, a 
property described by the coefficient M in the slope-activation 
equation. 
IV. DISCUSSION 
ENS therapy holds the potential to modulate or control the 
function of almost every tissue in the body. Control is 
established by artificially modulating the firing activity of 
existing neural pathways with patterned electrical impulses 
from an implantable or external device. To maximize control 
over the quality of the therapy, the correct strength and pattern 
of ENS must be applied to selectively activate and control one 
or more specific neural pathways to deliver a therapeutic 
message to target tissues, organs, or systems, whose state is 
measured in the form of a biomarker response. Establishing 
control is problematic, as the degree of neural activation in 
response to a given dose of stimulus varies greatly from 
patient to patient (e.g., due to genetic differences, the 
tissue/immune response to the implant, or environmental 
factors) and changes over time in individual patients [1, 5, 6]. 
Although relevant biomarkers remain to be discovered for 
many conditions, the degree of nerve activation is a useful 
marker that can be beneficially exploited for the immediate 
advancement of bioelectronic therapies [12], therapies that 
require fine control over neural pathways for maximal 
therapeutic benefit. 
 All existing ENS technology fails to fully account for 
patient sensitivity to the electrical stimulus, especially at the 
nerve-electrode interface. To titrate the strength of ENS 
therapy today, a physician programs the stimulator to deliver a 
set of treatment parameters that describe the strength and 
pattern of electrical stimulation. Over a period of weeks to 
months, a physician slowly adjusts these parameters on a 
patient-to-patient basis in an attempt to maximize benefit and 
limit side effects [1]. The degree of nerve activation is not 
monitored or tracked in relation to therapeutic benefit, 
however, so the physician must rely on his/her past experience 
and patient reports for guidance. Months of subjectively 
guided treatment parameter adjustments can induce variable 
adverse side effects and significant patient discomfort [5, 13, 
14]. Since the biological response to stimulation is not 
measured (neural activation or other biomarker), the stimulus 
parameters cannot be adjusted to maintain a constant degree of 
neural activation or therapeutic benefit over time.  
ANC is a form of artificial intelligence that adjusts stimulus 
parameters in real time so that control is maintained over one 
or more neural pathways that mediate the target therapeutic 
effect and the off target effects (i.e., side effects). With the 
closed-loop, biofeedback-driven control provided by ANC, the 
degree of nerve fiber activation, ranging from 0 to 100%, is 
controlled in the same manner across patients and within the 
same patient over time. ANC serves as a tool to advance our 
understanding of the relationships between the degree and 
pattern of neural activation and therapeutic efficacy. 
Moreover, it allows for the rapid if not immediate deployment 
of stimulus parameters that are optimized for each patient, 
nerve and neuron type. It is a new alternative to the long, 
burdensome device tuning system that is currently in use that 
can pave the way for a new standard of care. 
V. CONCLUSION 
ANC is device agnostic and modular in design, creating 
opportunities to develop additional subsystems that 
autonomously adjust the nerve activation level according to 
disease or stimulus-driven changes in the health of a patient 
(e.g., responsive or adaptive stimulation). Toward this end, 
ANC can accept a growing number of biological markers as 
input. Through collaboration, we expect to rapidly expand the 
capabilities of ANC and promote its use in the development of 
next-generation bioelectronic therapies. Under this paradigm, 
ANC will operate in tandem with secondary closed-loop 
systems, which instruct ANC when and how to activate select 
neuron populations in a nerve based on detected physiological 
events captured in the form of a biomarker (e.g., seizure 
onset). As a tool for unraveling the relationships between 
neural activation, biomarker changes and therapeutic benefit, 
ANC will further contribute to our understanding of treatment-
resistant neurological diseases, their cause, their treatment and 
their prevention.  
 
Fig. 7. Activation profile 
for Aγ (left), B (middle-
left) and C (middle-right) 
fibers with predicted CD 
lines (top row) and SD 
curves (bottom row) for 0 
to 100% maximal 
activation, in 10% 
increments. The right 
column shows the NAP, 
which predicts how all 
Aγ, B and C fibers in the 
nerve will respond to any 
strength of stimulation. 
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